Literature DB >> 33659325

Assessments of HLA-I Specificities of Anti-HLA-I Monoclonal Antibodies Using Solid Phase Bead Arrays.

Anita J Zaitouna1, Daniel S Ramon2, Malini Raghavan1.   

Abstract

Human leukocyte antigen class I (HLA-I) molecules are a group of structurally-related cell surface proteins with a high degree of variability within the population. While only up to six variants are expressed in an individual person, the whole population contains thousands of different variants. The ability to distinguish specific variants is important in the clinic to determine compatibility during organ and bone marrow transplantation and in the laboratory to study the biological properties of individual variants. Solid phase bead arrays contain purified, individually identifiable HLA-I molecules that can be used to determine antibody specificity for individual HLA-I proteins. This method is high-throughput, highly specific, and allows for simultaneous screening of antibodies against multiple HLA-I allotypes. The beads are particularly useful for screening patient sera for the presence of donor-specific antibodies against individual HLA-I variants (which can arise during pregnancy, blood transfusion, or organ transplantation). Alternate approaches, such as the use of individual HLA-I-expressing cell lines, are more time consuming, and such cell lines are difficult to procure and standardize. The HLA-I beads are also useful to study HLA-I specificity and selectivity for other receptors and binding partners.
Copyright © The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Affinity; Bead array; Immunology; Luminex beads; Monoclonal antibodies; Specificity

Year:  2020        PMID: 33659325      PMCID: PMC7842659          DOI: 10.21769/BioProtoc.3655

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  8 in total

1.  Immunoaffinity chromatography.

Authors:  T A Springer
Journal:  Curr Protoc Mol Biol       Date:  2001-05

Review 2.  Strategies for the measurements of expression levels and half-lives of HLA class I allotypes.

Authors:  Malini Raghavan; Brogan Yarzabek; Anita J Zaitouna; Sujatha Krishnakumar; Daniel S Ramon
Journal:  Hum Immunol       Date:  2019-02-05       Impact factor: 2.850

3.  Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6.

Authors:  C A Müller; G Engler-Blum; V Gekeler; I Steiert; E Weiss; H Schmidt
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

4.  Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity.

Authors:  Brogan Yarzabek; Anita J Zaitouna; Eli Olson; Gayathri N Silva; Jie Geng; Aviva Geretz; Rasmi Thomas; Sujatha Krishnakumar; Daniel S Ramon; Malini Raghavan
Journal:  Elife       Date:  2018-07-10       Impact factor: 8.140

5.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

6.  Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.

Authors:  Nils Lachmann; Kremena Todorova; Harald Schulze; Constanze Schönemann
Journal:  Transfus Med Hemother       Date:  2013-05-08       Impact factor: 3.747

7.  Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.

Authors:  F Tudor Ilca; Linnea Z Drexhage; Gemma Brewin; Sarah Peacock; Louise H Boyle
Journal:  Cell Rep       Date:  2019-11-05       Impact factor: 9.423

8.  Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1.

Authors:  Wilfredo F Garcia-Beltran; Angelique Hölzemer; Gloria Martrus; Amy W Chung; Yovana Pacheco; Camille R Simoneau; Marijana Rucevic; Pedro A Lamothe-Molina; Thomas Pertel; Tae-Eun Kim; Haley Dugan; Galit Alter; Julie Dechanet-Merville; Stephanie Jost; Mary Carrington; Marcus Altfeld
Journal:  Nat Immunol       Date:  2016-07-25       Impact factor: 25.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.